Navigation Links
Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
Date:3/7/2012

BURLINGAME, Calif. and LONGNAN CITY, China, March 6, 2012  /PRNewswire/ -- Apexigen, Inc., a privately held biopharmaceutical company, and Gansu Duyiwei Biological Pharmaceutical Co., Ltd. (GDBP), which is listed on the Shenzhen stock exchange, today announced that they entered into a collaboration to grant an exclusive license to GDBP to develop and commercialize APX004 in China.   APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases.  Under this agreement, GDBP will have an exclusive license and sole responsibility to research, develop and commercialize APX004 in China.  Apexigen retains all rights to APX004 outside of China and will collaborate with GDBP to advance the development program.  Under the terms of the agreement, Apexigen will receive an upfront payment, milestone payments on the successful achievement of regulatory milestones, and a royalty.  Financial terms were not disclosed.

"The pharmaceutical market in China today is very dynamic.  We are pleased to be partnering with Gansu Duyiwei for the development and commercialization of APX004 in this vibrant market.  We're looking forward to a productive partnership," said Dr. Xiaodong Yang, Apexigen's President and CEO.  

"During the last century, people often said that the century to come will be the biological science century.  The report of a survey from an American marketing research institute, Alt Assets, shows that the prospects for the global biotechnology industry are very promising. The sales revenue for products of the bio-economy, that is, products based on biological science and biotechnology, will exceed 15 trillion US Dollars in 30 years and the bio-economy will outrun the information economy and become the most powerful economic force in the world. The cooperation between Duyiwei and Apexigen will become a developmental milestone for Duyiwei. Based on its efforts, flexible mode of R&D and the continually increased investment on R&D, Duyiwei has the confidence and determination to constantly launch a series of original products in the near future to bring hope to the diseased and improve their quality of living," said Dr. Zhiping Duan, CEO of Gansu Duyiwei.

About Apexigen, Inc.

Apexigen, Inc. is an emerging biopharmaceutical company focused on the development of best-in-class antibody therapeutics for the treatment of cancer and other serious diseases.  Apexigen has a robust antibody platform technology and a pipeline of seven humanized antibody product candidates.  Apexigen's proprietary antibody technologies produce a broad diversity of antibodies with high specificity and high affinity against unique epitopes.  It can successfully generate antibodies against challenging antigens where competing technologies fail.  This technology allows Apexigen to identify antibodies with unique functional characteristics for optimal therapeutic benefit.

Developing its product pipeline through collaborations is an important aspect of Apexigen's business model.  Several antibodies derived from its technology have been licensed to companies in China who are developing them for commercialization there.  In addition, Apexigen has also licensed the use of its antibody technologies to multinational companies for use in the development of therapeutics worldwide.  Additional information is available at www.apexigen.com.

About Gansu Duyiwei Biological Pharmaceutical Co., Ltd.

Gansu Duyiwei Biological Pharmaceutical Co., Ltd. is located in Kang County, Longnan city , Gansu Province. As the first pharmaceutical company listed on Shenzhen Stock Exchange in Gansu Province, the company has developed very fast in recent years.

As an important Chinese patent medicine and crude drug company based in west China, its development has been a strong impetus to the rapid development of the local economy. We made outstanding contributions to poverty in the western region. We have been awarded over the years with the titles of "high-tech enterprises in Gansu Province","a key leading enterprise of agricultural industrialization in Gansu Province, and "Longnan excellent enterprise". Our main product is "Duyiwei Capsule" and it has been named as a brand-name product in Gansu Province and a top-quality product in Longnan for three years.

Our products include 11 dosage forms and 32 varieties, most of which are Traditional Chinese Medicine, which provide therapy in the areas of Hemostasis & Analgesia, Cardiovascular system, Respiratory system , Nervous system , Urinary system and so on.

CONTACT:  Mark Nevins, +1-650-931-6236, ext. 502, mnevins@apexigen.com


'/>"/>
SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
2. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
3. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
4. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
5. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
6. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
7. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
8. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
9. Pharma and Biotech Leaders to Converge in Shanghai
10. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
11. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 19, 2017 , ... Participants of this educational webinar will ... Along with the advantages and disadvantages of ductless, filtered fume hoods, they will ... laboratory. , Attendees will learn from an industry expert about the different types ...
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® pocket ... testers even stand upright with a new cap design that is versatile, functional and ... field who need to test water quality. , The Oakton pocket testers have many ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... pleased to announce the recipients of its 2017 Science Student Award. The scholarship ... qualities, and involvement with community service defray the costs of obtaining their science ...
(Date:9/19/2017)... Charlotte, NC (PRWEB) , ... September 19, 2017 ... ... focusing on band technologies for surgical applications, announced today that two new patents ... System. , Michael Albert, MD, Co-Founder of Band-LOK, said, “We continue to explore ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
Breaking Biology News(10 mins):